Compare GM & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GM | BSX |
|---|---|---|
| Founded | 1908 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.5B | 66.3B |
| IPO Year | 2010 | 2010 |
| Metric | GM | BSX |
|---|---|---|
| Price | $82.64 | $44.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 22 |
| Target Price | ★ $93.86 | $93.18 |
| AVG Volume (30 Days) | 6.1M | ★ 17.2M |
| Earning Date | 04-28-2026 | 04-22-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | ★ 55.20 |
| EPS | ★ 4.25 | 0.90 |
| Revenue | ★ $185,019,000,000.00 | $9,076,000,000.00 |
| Revenue This Year | $3.56 | $11.85 |
| Revenue Next Year | $2.38 | $10.16 |
| P/E Ratio | ★ $18.98 | $48.42 |
| Revenue Growth | N/A | ★ 12.49 |
| 52 Week Low | $51.69 | $42.20 |
| 52 Week High | $87.62 | $109.50 |
| Indicator | GM | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 60.14 | 46.85 |
| Support Level | $78.75 | $42.23 |
| Resistance Level | $84.34 | $46.37 |
| Average True Range (ATR) | 2.33 | 1.17 |
| MACD | 0.67 | 0.29 |
| Stochastic Oscillator | 77.03 | 55.04 |
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under three segments: GM North America, GM International, and GM Financial. The United States now has four brands instead of eight under old GM. The company regained its US market share leadership in 2022, after losing it to Toyota due to the chip shortage in 2021. 2025 US share was 17.4%, up 60 basis points from 2024. The Cruise autonomous vehicle arm, which GM now owns outright, previously operated driverless geofenced AV robotaxi services in San Francisco and other cities, but after a 2023 accident, GM decided that it will focus on personal AVs. GM Financial became the company's captive finance arm in 2010 via the purchase of AmeriCredit.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.